Education Archive

HPV vaccine effective in women aged 24-45 not already infected with HPV

The quadrivalent HPV vaccine is efficacious in women aged 24—45 years not previously infected with vaccine HPV types. This is the conclusion from a randomised trial reported in the current issue of The Lancet.

Vaccine efficacy against HPV 6, 11, 16, and 18 in the per-protocol group (i.e. women not previously exposed to the relevant HPV types) was 90·5%. In the intention-to-treat population (women who had not been completely vaccinated and/or had pre-existing HPV infection), efficacy was much lower at 30·9%.